Saxony Capital Management LLC Invests $203,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Saxony Capital Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,426 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.

Several other hedge funds have also recently bought and sold shares of GILD. Sunbelt Securities Inc. boosted its holdings in Gilead Sciences by 26.4% in the first quarter. Sunbelt Securities Inc. now owns 11,603 shares of the biopharmaceutical company’s stock valued at $850,000 after acquiring an additional 2,426 shares during the last quarter. Brookstone Capital Management boosted its stake in Gilead Sciences by 751.1% in the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock valued at $9,322,000 after acquiring an additional 112,305 shares during the period. Future Financial Wealth Managment LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $161,000. Matrix Asset Advisors Inc. NY boosted its position in shares of Gilead Sciences by 4.8% during the first quarter. Matrix Asset Advisors Inc. NY now owns 311,545 shares of the biopharmaceutical company’s stock worth $22,821,000 after buying an additional 14,200 shares during the period. Finally, DGS Capital Management LLC boosted its position in shares of Gilead Sciences by 13.1% during the first quarter. DGS Capital Management LLC now owns 8,809 shares of the biopharmaceutical company’s stock worth $645,000 after buying an additional 1,021 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD stock opened at $88.16 on Wednesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $88.36. The stock has a market cap of $109.83 billion, a PE ratio of 244.89, a P/E/G ratio of 2.98 and a beta of 0.18. The firm has a 50 day simple moving average of $81.61 and a two-hundred day simple moving average of $73.07.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.49%. The ex-dividend date was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GILD. Barclays upped their target price on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Truist Financial boosted their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Wells Fargo & Company upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $78.00 to $100.00 in a report on Monday, October 7th. Finally, Royal Bank of Canada upped their price objective on shares of Gilead Sciences from $74.00 to $75.00 and gave the stock a “sector perform” rating in a report on Friday, October 4th. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.85.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.